I don't know about this Mr. P. Yes the stock is looking like something bad is about to happen but.... Everything that I have heard is that the Peer Review could be in its final stages and could be released at any time. Now this is coming from the same people that has been telling us all great things as the stock is about ready to hit a 52 week low. What I keep hearing is that the peer review will be nothing short of very good and might be the best peer review ever seen for Alzheimer's. So that really is not much as we only have a few drugs approved and we know that they suck. So having a peer review that is better than any other drug out there should be huge news and could be the springboard for the stock to turn around rapidly. When that happens who knows but when I asked IR this question about 10 days ago, they said that it could happen soon with the caveat that they are not in control of the release date. Also, I think that if it is really the best Alz peer review, it must be in a top tier publication. We have seen all the results that are public and I think that we all agree that even with some level of failure within the trial we are still head and shoulders above all others. That tells me we have a great peer review coming and it should be in a very influential publication. So once that happens lets say in the next 1-4 months, doesn't that open us up to a positive ema and fda review and very possibly increased partner activity. I would think that we get information in this order : first peer review, then we have the marketing of the peer review ( whatever that might be ), FDA guidance on Alz and Rett, submission of the EMA Application in about 4 months, submission of the alz FDA NDA in approx 5-6 months, Rett approval by the FDA early 4th qtr., FDA acceptance of Alz NDA and PDUFA date given of April 1, 2025. I think 2024 q3 and q4 will be our huge move timeframes but also peer review and FDA guidance will be huge as well. Just a few more month of pain or $4.90 whichever comes first.
